Management of imatinib-resistant patients with chronic myeloid leukemia

被引：105

作者：

Bhamidipati, Pavan Kumar ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Cortes, Jorge ^{[1
]}

Cornelison, A. Megan ^{[1
]}

Jabbour, Elias ^{[1
]}

机构：

[1] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Box 428, Houston, TX 77030 USA

来源：

THERAPEUTIC ADVANCES IN HEMATOLOGY | 2013年 / 4卷 / 02期

关键词：

CML; imatinib resistance; treatment; tyrosine kinase inhibitor;

D O I：

10.1177/2040620712468289

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Since its approval in 2001 for frontline management of chronic myelogenous leukemia (CML), imatinib has proven to be very effective in achieving high remission rates and improving prognosis. However, up to 33% of patients will not achieve optimal response. This has led researchers to develop new second- and third-generation tyrosine kinase inhibitors. In this article, we review the mechanisms of resistance, recommendations for monitoring, assessment of milestones, and management options for patients with CML who are resistant to imatinib therapy. We further explain the potential pitfalls that can lead to unnecessary discontinuation, the prognosis of patients whose condition fails to respond to treatment, and the upcoming therapies.

引用

页码：103 / 117

页数：15

共 79 条

[1]

Significance of Suboptimal Response to Imatinib, as Defined by the European LeukemiaNet, in the Long-Term Outcome of Patients With Early Chronic Myeloid Leukemia in Chronic Phase [J].

Alvarado, Yesid ;

Kantarjian, Hagop ;

O'Brien, Susan ;

Faderl, Stefan ;

Borthakur, Gautam ;

Burger, Jan ;

Wierda, William ;

Garcia-Manero, Guillermo ;

Shan, Jianqin ;

Cortes, Jorge .

CANCER, 2009, 115 (16) :3709-3718

[2]

Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up [J].

Baccarani, M. ;

Dreyling, M. .

ANNALS OF ONCOLOGY, 2009, 20 :105-107

[3]

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].

Baccarani, Michele ;

Saglio, Giuseppe ;

Goldman, John ;

Hochhaus, Andreas ;

Simonsson, Bengt ;

Appelbaum, Frederick ;

Apperley, Jane ;

Cervantes, Francisco ;

Cortes, Jorge ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Frangois ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Niederwieser, Dielger ;

Silver, Richard ;

Hehlmann, Rudiger .

BLOOD, 2006, 108 (06) :1809-1820

[4]

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet [J].

Baccarani, Michele ;

Cortes, Jorge ;

Pane, Fabrizio ;

Niederwieser, Dietger ;

Saglio, Giuseppe ;

Apperley, Jane ;

Cervantes, Francisco ;

Deininger, Michael ;

Gratwohl, Alois ;

Guilhot, Francois ;

Hochhaus, Andreas ;

Horowitz, Mary ;

Hughes, Timothy ;

Kantarjian, Hagop ;

Larson, Richard ;

Radich, Jerald ;

Simonsson, Bengt ;

Silver, Richard T. ;

Goldman, John ;

Hehlmann, Rudiger .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (35) :6041-6051

[5]

Bixby Dale, 2009, Hematology Am Soc Hematol Educ Program, P461, DOI 10.1182/asheducation-2009.1.461

[6]

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis [J].

Branford, S ;

Rudzki, Z ;

Walsh, S ;

Parkinson, I ;

Grigg, A ;

Szer, J ;

Taylor, K ;

Herrmann, R ;

Seymour, JF ;

Arthur, C ;

Joske, D ;

Lynch, K ;

Hughes, T .

BLOOD, 2003, 102 (01) :276-283

[7]

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? [J].

Branford, Susan ;

Melo, Junia V. ;

Hughes, Timothy P. .

BLOOD, 2009, 114 (27) :5426-5435

[8]

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate [J].

Brave, Michael ;

Goodman, Vicki ;

Kaminskas, Edvardas ;

Farrell, Ann ;

Timmer, William ;

Pope, Sarah ;

Harapanhalli, Ravi ;

Saber, Haleh ;

Morse, David ;

Bullock, Julie ;

Men, Angela ;

Noory, Carol ;

Ramchandani, Roshni ;

Kenna, Leslie ;

Booth, Brian ;

Gobburu, Joga ;

Jiang, Xiaoping ;

Sridhara, Rajeshwari ;

Justice, Robert ;

Pazdur, Richard .

CLINICAL CANCER RESEARCH, 2008, 14 (02) :352-359

[9]

Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519 [J].

Che, XF ;

Nakajima, Y ;

Sumizawa, T ;

Ikeda, R ;

Ren, XQ ;

Zheng, CL ;

Mukai, M ;

Furukawa, T ;

Haraguchi, M ;

Gao, H ;

Sugimoto, Y ;

Akiyama, S .

CANCER LETTERS, 2002, 187 (1-2) :111-119

[10]

Chu E., 2010, CANC CHEMOTHERAPY DR

← 1 2 3 4 5 6 7 8 →